Modern Wealth Management LLC Grows Stock Holdings in Boston Scientific Corporation $BSX

Modern Wealth Management LLC raised its position in shares of Boston Scientific Corporation (NYSE:BSX) by 7.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,974 shares of the medical equipment provider’s stock after buying an additional 218 shares during the period. Modern Wealth Management LLC’s holdings in Boston Scientific were worth $300,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. 1248 Management LLC purchased a new position in shares of Boston Scientific during the first quarter worth $26,000. Y.D. More Investments Ltd acquired a new stake in shares of Boston Scientific in the first quarter valued at $27,000. Investment Management Corp VA ADV acquired a new stake in shares of Boston Scientific in the fourth quarter valued at $25,000. Sunbeam Capital Management LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at $26,000. Finally, Ameriflex Group Inc. acquired a new stake in shares of Boston Scientific in the fourth quarter valued at $31,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on BSX. Citigroup reiterated a “buy” rating and issued a $125.00 price objective (up from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. UBS Group increased their price objective on Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Thursday, July 24th. Truist Financial increased their price objective on Boston Scientific from $120.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, July 24th. Leerink Partners began coverage on Boston Scientific in a research note on Monday, June 16th. They issued an “outperform” rating and a $118.00 price objective on the stock. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of Boston Scientific in a research note on Thursday, July 24th. Three analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, Boston Scientific has an average rating of “Buy” and a consensus target price of $118.04.

Boston Scientific Stock Performance

Shares of BSX stock opened at $99.75 on Tuesday. Boston Scientific Corporation has a 52-week low of $80.64 and a 52-week high of $109.50. The stock’s 50-day moving average price is $104.78 and its 200 day moving average price is $102.24. The stock has a market capitalization of $147.80 billion, a PE ratio of 59.38, a price-to-earnings-growth ratio of 2.47 and a beta of 0.65. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the previous year, the company earned $0.62 EPS. The firm’s revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insiders Place Their Bets

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $105.43, for a total value of $5,271,500.00. Following the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $18,802,597.06. The trade was a 21.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the sale, the director directly owned 2,081 shares in the company, valued at $222,646.19. This represents a 58.23% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock worth $18,397,457 over the last quarter. 0.50% of the stock is owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.